Skip to Main Content

Celgene is getting a pipeline confidence boost courtesy of its friends at Acceleron Pharma. Next, Celgene can help itself by raising financial guidance for the rest of the year.

On Monday night, Celgene and Acceleron said their partnered drug luspatercept met all primary and secondary endpoints in a Phase 3 clinical trial of patients with transfusion-dependent beta thalassemia. The good news was a fast follow to a similar win for luspatercept in a Phase 3 trial involving patients with another blood disease — myelodysplastic syndrome.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.